Ischemix Board of Directors

Reinier Beeuwkes, Ph.D. - Chairman

Dr. Beeuwkes joined Ischemix in 2002 as a Director and was appointed President/CEO in 2005. Dr. Beeuwkes began his career working with Nobelist Bernard Lown on “cardioversion”, the electrical correction of cardiac arrhythmia. From 1970 to 1982, Dr. Beeuwkes held a faculty position at Harvard Medical School. His work centered on the microcirculation of the kidney and heart, and resulted in more than 80 publications, including four chapters in renal textbooks and three award-winning kidney teaching films. With A. Clifford Barger, he discovered the association of coronary vasa vasorum with atherosclerotic plaque. This work is widely ited in myocardial infarction literature.

In 1982, Dr. Beeuwkes co-founded Braintree Laboratories, a privately held pharmaceutical company which pioneered products for colonoscopy. From 1982-1987, he served as Director of Renal and Cardiovascular Pharmacology at Smith Kline and French Laboratories and Director of Strategic Planning for SmithKline Worldwide R&D. He holds nine U.S. patents. Dr. Beeuwkes earned his B.S. from The Massachusetts Institute of Technology and his Ph.D. from Harvard University.

Back to top

Geoffrey E. Clark, M.D. - Director

Dr. Clark was a co-founder and first Medical Director of Braintree Laboratories, Inc. He has been instrumental in preparing the clinical and toxicological sections of several New Drug Applications, as well as designing and monitoring clinical trials. He has also been responsible for the preparation of FDA reports for marketed pharmaceuticals. In addition to his responsibilites at Braintree Laboratories, he has maintained an active clinical practice for more than 30 years. Dr Clark graduated from Harvard College and received his medical degree at the State University of New York at Buffalo. There he conducted research in nutritional science and immunology. He returned to Boston to complete his internship, residency and fellowship training at the Harvard Medical School services of Cambridge and Boston City Hospitals.

Back to top

John A. Norris, J.D., M.B.A. - Director

John A. Norris, J.D., M.B.A., is a former Deputy Chief of the US Food and Drug Administration, currently President and CEO of Norris Capital, and a faculty member of the Harvard School of Public Health. Previously, Mr. Norris co-founded seven companies, including Coprindm, now DecisionView, a developer of Performance Optimization and Management technology and solutions for the life sciences industry, with specific focus on the area of clinical trials; and PrivaSource, a privacy and information security firm enabling health data handling in compliance with the state and federal (HIPAA) patient privacy regulation.

Prior to this, he was Corporate Executive Vice President and Worldwide Managing Director, Life Sciences, for Hill and Knowlton, a global marketing and management consulting firm. Prior to Hill and Knowlton, Mr. Norris was the Chief Operating Officer of the FDA. He also served as subject matter expert and advisor to a US President and several branches of the US Government. He teaches FDA-related matters and reimbursement regulation at Harvard, has advised top pharmaceutical executives, including those at Merck, Pfizer, Glaxo and Johnson & Johnson, and serves on several corporate boards. He received his J.D. and M.B.A. degrees from Cornell University and his advanced certificate in government from Harvard University.

Back to top

Edward Shashoua, D.O. - Director

Dr. Shashoua is the son of the late scientific founder; Dr. Victor Shashoua. He is currently in a multi-specialty practice at Harvard Vanguard Medical Associates. Dr. Shashoua began his career in real estate and studied medicine receiving his degree from the University of New England in Maine. He trained in Internal Medicine at Roger Williams Medical Center, an affiliate of Boston University Medical School.

Back to top